Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-07-12 pm EDT 5-day change 1st Jan Change
22.5 USD +2.46% Intraday chart for Rocket Pharmaceuticals, Inc. +12.73% -24.92%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Canaccord Genuity Adjusts Price Target on Rocket Pharmaceuticals to $40 From $49, Maintains Buy Rating MT
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 3000 Value Index CI
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 2500 Value Index CI
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell Small Cap Comp Value Index CI
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 2000 Value Index CI
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 3000E Value Index CI
Needham Trims Price Target on Rocket Pharmaceuticals to $52 From $53, Maintains Buy Rating MT
Rocket Pharmaceuticals Says FDA Seeks More Information on Kresladi MT
Rocket Pharmaceuticals Shares Slide After FDA Rejects Kresladi DJ
FDA Turns Away Rocket Pharma's Gene Therapy, Seeks More Data DJ
US FDA declines to approve Rocket Pharma's immune disorder gene therapy RE
Rocket Pharmaceuticals, Inc. Provides Regulatory Update on KRESLADI? (marnetegragene autotemcel; marne-cel) CI
Rocket Pharmaceuticals' Gene Therapy for Inherited Heart Disease Receives Orphan Drug Designation in Europe MT
Transcript : Rocket Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM
UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating MT
Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise MT
Rocket Pharmaceuticals Presents Positive Data from Lv Hematology Portfolio At the 27Th Annual Meeting of the American Society of Gene and Cell Therapy CI
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing MT
Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing MT
Rocket Pharmaceuticals Says European Medicines Agency Accepted Marketing Authorization Application for RP-L102 MT
Goldman Sachs Initiates Rocket Pharmaceuticals at Neutral With $39 Price Target MT
Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia CI
Rocket Pharmaceuticals Appoints Aaron Ondrey as CFO MT
Rocket Pharmaceuticals, Inc. Announces Appointment of Aaron Ondrey as Chief Financial Officer CI
Chart Rocket Pharmaceuticals, Inc.
More charts
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
22.5 USD
Average target price
47.38 USD
Spread / Average Target
+110.60%
Consensus
  1. Stock Market
  2. Equities
  3. RCKT Stock
  4. News Rocket Pharmaceuticals, Inc.
  5. Rocket Pharmaceuticals' Gene Therapy for Inherited Heart Disease Receives Orphan Drug Designation in Europe